Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01598324 · ClinicalTrials.gov registry record
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder
A clinical trial, sponsored by Mclean Hospital.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01598324: Clinical Trial study, sponsored by Mclean Hospital.
NCT01598324 is a clinical trial that was terminated before completion, run by Mclean Hospital. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01598324 was terminated before completion, sponsored by Mclean Hospital.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This is an ancillary study to a clinical trial that is being conducted at Massachusetts General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy of ziprasidone together with escitalopram for treatment-resistant depression (NCT00633399). This observational study will involve magnetic resonance scans to examine brain chemistry (neurotransmitter levels), brain activity, and functional connections between brain regions before and after participating in the trial. The neurotransmitters of interest are glutamate, glutamine, and GABA. Comparisons will be made between individuals who receive ziprasidone and individuals who receive an inactive placebo. Differences between participants who respond to standard antidepressants and those who require additional medication will also be examined. All participants will have a baseline magnetic resonance scan before starting medication. The second scan will be after 8 weeks of escitalopram treatment for those who respond or following 8 weeks of escitalopram plus ziaprasidone or placebo (16 weeks after starting) for those who do not respond to escitalopram alone. Participants will complete standard rating scales for depression at each visit.
Primary Outcome
Glutamate levels are measured by magnetic resonance spectroscopy 8 weeks after starting treatment with ziprasidone or placebo in addition to escitalopram.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-07 |
Why NCT01598324 stopped before completion
NCT01598324 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01598324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01598324 about?
NCT01598324 is a clinical study titled "Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder". This is an ancillary study to a clinical trial that is being conducted at Massachusetts General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy of ziprasidone together with escitalopram for treatment-resistant depression (NCT00633399). This observational study wil...
What is the current status of trial NCT01598324?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2012-07.
Who is sponsoring clinical trial NCT01598324?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia